Application of low-dose cardioplegia cardiac perfusion in single valve surgery
Guo Yibai
Liang Bing
Zhang Yiwen
Liu Yu
Abstract：Objective To evaluate the feasibility of replacing conventional doses of histidine tryptophan ketoglutarate(HTK)perfusion solution with a low-dose HTK solution for myocardial protection in single valve surgery.Methods A retrospective analysis was conducted on the clinical data of 184 cases of single valve surgery in the Cardiovascular Department of the General Hospital of the Northern Theater Command from August 2023 to December 2023.Patients were divided into the low-dose group(n=81)and the conventional-dose group(n=83)based on the intraoperative dosage of HTK perfusion solution Clinical data,including cardiac troponin(cTNT),creatine kinase-MB(CKMB),surgical procedures,extracorporeal circulation time(ECC),aortic cross-clamp(ACC)time,left ventricular ejection fraction(LVEF),postoperative ICU time,length of hospital stay,and mortality rate,were collected and analyzed.Results There were no significant difference in baseline characteristics between the two groups(P>0.05).The low-dose group demonstrated a significantly shorter perfusion time compared to the conventional-dose group(P<0.05).No significant differences were observed in ECC time,ACC time,postoperative cTNT,levels,mechanical ventilation duration,and ICU stay time between the low groups.Conclusion Low-dose HTK perfusion is safe and feasible in single valve surgery,achieving comparable clinical outcomes to conventional-dose perfusion.
Keywords：Histidine-Tryptophan-Ketoglutarate solutionValve surgeryMyocardial protectionTroponin TLow-dose perfusion
Publication Date：2025-02-27
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：5( 40-43,57 )